More recently, professor Vadim V Klimontov demonstrated that the anti-albuminuric effect of EMPA could be attributed to mitigation of podocyte injury and enhancement of nephrin expression so as to attenuate podocytopathy in experimental diabetic kidney disease [16]. The gene discussed is NPHS1; the disease is diabetic kidney disease.